Clinical Updates: Primary Therapy of Multiple Myeloma

The FDA approvals of new regimens and new agents for supportive care including bone-directed therapy have led to rapid updates to the NCCN Guidelines for Multiple Myeloma. The American Cancer Society has estimated 30,770 people will be diagnosed with MM and 12,770 will die of it in 2018 in the United States. In order to improve these statistics, it is important to help clinicians to keep up-to-date with the newer treatment options available to help select the most efficient treatment strategy. In addition, knowledge of the relevant side effects of the novel drugs reported in pivotal clinical studies and strategies for their prevention and management is also equally important to improve overall patient outcomes.

Target Audience

This educational program is designed to meet the educational needs of oncology nurses who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:    

  • Discuss the rationale behind inclusion of new options for primary and bone-directed therapy in the NCCN Guidelines for Multiple Myeloma
  • Outline appropriate evidence-based management strategies for patients with newly diagnosed multiple myeloma taking patient characteristics into consideration
  • Learn the various adverse effects associated with multiple myeloma therapies reported in pivotal clinical studies
Additional information
Supporters: 

This activity is supported by an educational grant from:

  • AstraZeneca
  • Genentech
  • Pfizer
  • Taiho Oncology, Inc.

This activity is supported by an independent educational grant from Merck & Co., Inc.

Course summary
Available credit: 
  • 0.73 ANCC contact hours
  • 0.73 Participation
Course opens: 
05/15/2019
Course expires: 
05/15/2020
Cost:
$0.00

Yi Lisa Hwa, APRN, CNP, DNP
Mayo Clinic Cancer Center

 

NCCN Medical Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions 

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers 

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses no relevant financial relationships:

Yi Lisa Hwa, APRN, CNP, DNP

NCCN Staff Disclosures

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:

Robert W. Carlson, MD; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa G. Kimbro, MBA, CPA (Employed by NCCN until 8/10/18); Wui-Jin Koh, MD; Joan S. McClure, MS (Employed by NCCN until 8/1/18); Lisa Perfidio, MS; Sarah Sinclair; Kathy Ann Smith, CHCP; Gary J. Weyhmuller, MBA, SPHR

The NCCN Clinical staff listed below discloses no relevant financial relationships:

Rashmi Kumar, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this educational activity for a maximum of  0.73 contact hours.

Available Credit

  • 0.73 ANCC contact hours
  • 0.73 Participation

Accreditation Period

Course opens: 
05/15/2019
Course expires: 
05/15/2020

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: